Search Results - "Herraez, A. Casado"

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions by Karam, A., Ledermann, J.A., Kim, J.-W., Sehouli, J., Lu, K., Gourley, C., Katsumata, N., Burger, R.A., Nam, B.-H., Bacon, M., Ng, C., Pfisterer, J., Bekkers, R.L.M., Casado Herráez, A., Redondo, A., Fujiwara, H., Gleeson, N., Rosengarten, O., Scambia, G., Zhu, J., Okamoto, A., Stuart, G., Ochiai, K.

“…The consensus statements regarding first-line therapies in women with ovarian cancer, reached at the Fifth Ovarian Cancer Consensus Conference held in Tokyo,…”
Get full text

Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial by Mirza, Mansoor R., Benigno, B., Dørum, A., Mahner, S., Bessette, P., Barceló, I. Bover, Berton-Rigaud, D., Ledermann, J.A., Rimel, B.J., Herrstedt, J., Lau, S., du Bois, A., Herráez, A. Casado, Kalbacher, E., Buscema, J., Lorusso, D., Vergote, I., Levy, T., Wang, P., de Jong, F.A., Gupta, D., Matulonis, U.A.

“…Niraparib is a poly(ADP-ribose) polymerase (PARP) inhibitor approved for use in heavily pretreated patients and as maintenance treatment in patients with…”
Get full text

SEOM Clinical Guideline of management of soft-tissue sarcoma (2020) by de Juan Ferré, A., Álvarez Álvarez, R., Casado Herráez, A., Cruz Jurado, J., Estival González, A., Martín-Broto, J., Martínez Marín, V., Moreno Vega, A., Sebio García, A., Valverde Morales, C.

“…Soft-tissue sarcomas constitute an uncommon and heterogeneous group of tumors of mesenchymal origin. Diagnosis, treatment, and management should be performed…”
Get full text

Usefulness of Omalizumab in Rapid Drug Desensitization in Patients with Severe Anaphylaxis Induced by Carboplatin: Open Questions by Sánchez-Morillas, L, Casado Herráez, A, Rubio-Perez, M, Robledo Echarren, T, González Gutiérrez, M L, Cimarra, M, Vázquez Cortés, S, Cerecedo, I, Fernández-Rivas, M

“…Carboplatin is an effective and well-tolerated chemotherapeutic agent used as first-line and subsequent treatment for ovarian cancer. Hypersensitivity…”
Get full text

Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study by Ledermann, J.A., Zurawski, B., Raspagliesi, F., De Giorgi, U., Arranz Arija, J., Romeo Marin, M., Lisyanskaya, A., Póka, R.L., Markowska, J., Cebotaru, C., Casado Herraez, A., Colombo, N., Kutarska, E., Hall, M., Jacobs, A., Ahrens-Fath, I., Baumeister, H., Zurlo, A., Sehouli, J.

“…Gatipotuzumab is a humanized monoclonal antibody recognizing the carbohydrate-induced epitope of the tumor-associated mucin-1 (TA-MUC1). This study aimed to…”
Get full text

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer by Makker, Vicky, Colombo, Nicoletta, Casado Herráez, Antonio, Santin, Alessandro D, Colomba, Emeline, Miller, David S, Fujiwara, Keiichi, Pignata, Sandro, Baron-Hay, Sally, Ray-Coquard, Isabelle, Shapira-Frommer, Ronnie, Ushijima, Kimio, Sakata, Jun, Yonemori, Kan, Kim, Yong Man, Guerra, Eva M, Sanli, Ulus A, McCormack, Mary M, Smith, Alan D, Keefe, Stephen, Bird, Steven, Dutta, Lea, Orlowski, Robert J, Lorusso, Domenica

“…Women with advanced endometrial cancer that progressed during platinum-containing therapy were randomly assigned to lenvatinib plus pembrolizumab or…”
Get full text

Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life by Brotto, Lori, Brundage, Michael, Hoskins, Paul, Vergote, Ignace, Cervantes, Andres, Casado, Herraez A., Poveda, A., Eisenhauer, Elizabeth, Tu, Dongsheng

“…Background A recent phase III trial compared the efficacy of cisplatin-topotecan (a topoisomerase I inhibitor) followed by carboplatin-paclitaxel (Arm 1)…”
Get full text

A phase II/III trial of hafnium oxide nanoparticles activated by radiotherapy in the treatment of locally advance soft tissue sarcoma of the extremity and trunk wall by Bonvalot, S., Rutkowski, P.L., Thariat, J., Carrere, S., Sunyach, M.-P., Saada, E., Agoston, P., Hong, A., Mervoyer, A., Rastrelli, M., Le Pechoux, C., Moreno, V., Li, R., Tiangco, B., Casado Herraez, A., Gronchi, A., Mangel, L., Hohenberger, P., Delannes, M., Papai, Z.

Get full text

Treatment guidelines in ovarian cancer by Poveda Velasco, A, Casado Herráez, A, Cervantes Ruipérez, A, Gallardo Rincón, D, García García, E, González Martín, A, López García, G, Mendiola Fernández, C, Ojeda González, B

“…National and international specialists have met with the aim of writing down the guidelines for the treatment of epithelial ovarian cancer (in the Spanish…”
Get full text

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial by Coleman, Robert L, Oza, Amit M, Lorusso, Domenica, Aghajanian, Carol, Oaknin, Ana, Dean, Andrew, Colombo, Nicoletta, Weberpals, Johanne I, Clamp, Andrew, Scambia, Giovanni, Leary, Alexandra, Holloway, Robert W, Gancedo, Margarita Amenedo, Fong, Peter C, O'Malley, David M, Armstrong, Deborah K, Garcia-Donas, Jesus, Swisher, Elizabeth M, Floquet, Anne, Konecny, Gottfried E, McNeish, Iain A, Scott, Clare L, Cameron, Terri, Maloney, Lara, Goble, Sandra, Grace, Caroline, Harding, Thomas C, Raponi, Mitch, Sun, James, Lin, Kevin K, Giordano, Heidi, Ledermann, Jonathan A, Buck, M, Dean, A, Friedlander, M L, Harnett, P, Scott, C L, Dirix, L, Vergote, I, Elit, L, Ghatage, P, Oza, A M, Plante, M, Provencher, D, Weberpals, J I, Floquet, A, Joly, F, Leary, A, Medioni, J, Tredan, O, You, B, El-Balat, A, Hänle, C, Krabisch, P, Neunhöffer, T, Pölcher, M, Wimberger, P, Amit, A, Kovel, S, Leviov, M, Safra, T, Shapira-Frommer, R, Stemmer, S, Bologna, A, Colombo, N, Lorusso, D, Sabbatini, R F, Scambia, G, Tamberi, S, Zamagni, C, Fong, P C, O'Donnell, A, Gancedo, M Amenedo, Garcia-Donas, J, Guerra, E M, Oaknin, A, Palacio, I, Romero, I, Sanchez, A, Banerjee, S N, Drew, Y, Jackson, D, Ledermann, J A, McNeish, I A, Parkinson, C, Powell, M, Buss, M K, Chambers, S K, Chen, L-m, Coleman, R L, Holloway, R W, Konecny, G E, Ma, L, Morgan, M A, Morris, R T, O'Malley, D M, Slomovitz, B M, Swisher, E M, Vanderkwaak, T, Vulfovich, M

“…Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of…”
Get full text

1926P Trabectedin plus radiotherapy on symptomatic advanced sarcoma patients: Results from the SYNERGIAS study - A Spanish group for research in sarcoma (GEIS) phase II study by Martin-Broto, J., Kopeckova, K., Azinovic, I., Jurado, J. Cruz, Guzmán, L., Alvarez, R.M., Herraez, A. Casado, Morales, C.M. Valverde, Sanchez, A. Redondo, Lleida, R. Teres, Gonzalez, A. Alvarez, Dolado, M.C., Doval, A., Belinchón, B., Merino, J.A., Mendez, R., Ledesma, P., Gutierrez, A., Da Silva Moura, D., Hindi Muñiz, N.

Get full text

LBA32 Principal results of the EORTC-1508 trial: A phase II randomised, multicentre study of bevacizumab vs atezolizumab and bevacizumab with acetylsalicylic acid or placebo in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma by Banerjee, S., Ottevanger, P.B., Sarivalasis, A., Le Scodan, R., Montes, A., Kroep, J.R., Romeo Marin, M., Casado Herraez, A., Auvray-Kuentz, M., Westermann, A.M., Lucas, B., Dangaj, D., Herrera, F., Wolfer, A., Coens, C., Vanlancker, M.B., Kandalaft, L., Coukos, G.

Get full text

525MO Updated efficacy and safety of lenvatinib (LEN) + pembrolizumab (pembro) vs treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775 by Makker, V., Colombo, N., Casado Herraez, A., Monk, B.J., Mackay, H., Santin, A.D., Miller, D.S., Moore, R.G., Baron-Hay, S.E., Ray-Coquard, I.L., Shapira-Frommer, R., Ushijima, K., Yonemori, K., Kim, Y.M., Guerra Alia, E.M., Sanli, U.A., Huang, J., McKenzie, J., Barresi, G., Lorusso, D.

Get full text

1509P Efficacy and safety of vimseltinib in tenosynovial giant cell tumour (TGCT): Phase II expansion by Blay, J-Y., Gelderblom, H., Rutkowski, P., Wagner, A., van de Sande, M., Falcon Gonzalez, A., Stacchiotti, S., Le Cesne, A., Alcindor, T., Serrano, C., Palmerini, E., Ravi, V., Casado Herraez, A., Seddon, B., Vallee, M., Jarecha, R., Sharma, M., Ruiz-Soto, R., Sherman, M.L., Tap, W.D.

Get full text

20MO Time to deterioration in quality of life in patients (pts) with advanced endometrial cancer (aEC) treated with lenvatinib plus pembrolizumab (L+P) or treatment of physician’s choice (TPC) by Lorusso, D., Colombo, N., Casado Herraez, A., Santin, A.D., Colomba, E., Miller, D.S., Fujiwara, K., Pignata, S., Baron-Hay, S.E., Ray-Coquard, I.L., Shapira-Frommer, R., Kim, Y.M., McCormack, M., Massaad, R., Martin Nguyen, A., Zhao, Q., McKenzie, J., Prabhu, V.S., Makker, V.

Get full text

994O - Lenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC) by Makker, V., Taylor, M.H., Aghajanian, C., Oaknin, A., Mier, J., Cohn, A.L., Marin, M Romeo, Lorenzo, R Bratos, Brose, M.S., DiSimone, C., Messing, M.J., Stepan, D.E., Dutcus, C.E., Wu, J., Schmidt, E.V., Orlowski, R.J., Sachdev, P., Shumaker, R., Herraez, A Casado

“…LEN is a multikinase inhibitor of VEGFR 1–3, FGFR 1–4, PDGFRα, RET, and KIT. PEMBRO is an anti-PD-1 antibody. We report final results of a cohort of patients…”
Get full text

Durvalumab plus tremelimumab for the treatment of patients (pts) with refractory and progressive advanced thyroid carcinoma: A phase II multicohort trial (DUTHY / GETNE T1812) by Hernando Cubero, J., Taberna Sanz, M., Carmona Bayonas, A., Iglesias, L., Grande, E., Trigo Perez, J.M., Grau, J.J., Lopez-Picazo, J.M., Castelo, B., Alonso Gordoa, T., Lorenzo, I., Casado Herraez, A., Ugidos, L., Munarriz, J., Lavernia, J., Capdevila, J.

Get full text

Lenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC) by Makker, V., Taylor, M.H., Aghajanian, C., Oaknin, A., Mier, J., Cohn, A.L., Marin, M Romeo, Lorenzo, R Bratos, Brose, M.S., DiSimone, C., Messing, M.J., Stepan, D.E., Dutcus, C.E., Wu, J., Schmidt, E.V., Orlowski, R.J., Sachdev, P., Shumaker, R., Herraez, A Casado

Get full text

1872TiP - Durvalumab plus tremelimumab for the treatment of patients (pts) with refractory and progressive advanced thyroid carcinoma: A phase II multicohort trial (DUTHY / GETNE T1812) by Hernando Cubero, J., Taberna Sanz, M., Carmona Bayonas, A., Iglesias, L., Grande, E., Trigo Perez, J.M., Grau, J.J., Lopez-Picazo, J.M., Castelo, B., Alonso Gordoa, T., Lorenzo, I., Casado Herraez, A., Ugidos, L., Munarriz, J., Lavernia, J., Capdevila, J.

“…Preliminary studies have suggested that the activity of anti-PD-1 immune check-point inhibitors in thyroid cancer is low. However, we hypothesize that…”
Get full text

1872TiPDurvalumab plus tremelimumab for the treatment of patients (pts) with refractory and progressive advanced thyroid carcinoma: A phase II multicohort trial (DUTHY / GETNE T1812) by Hernando Cubero, J, Taberna Sanz, M, Carmona Bayonas, A, Iglesias, L, Grande, E, Trigo Perez, J M, Grau, J J, Lopez-Picazo, J M, Castelo, B, Alonso Gordoa, T, Lorenzo, I, Casado Herraez, A, Ugidos, L, Munarriz, J, Lavernia, J, Capdevila, J

“…Abstract Background Preliminary studies have suggested that the activity of anti-PD-1 immune check-point inhibitors in thyroid cancer is low. However, we…”
Get full text